EYPT EyePoint Pharmaceutics LONG

NASDAQ:EYPT   EyePoint Pharmaceuticals, Inc.
EYPT is now on another breakout on the 2h chart similar to what occurred

from mid-December to mid-January. On the indicators the MACD shows

the K/D lines on a steep upward slope. For me, what set off my interest

was a relative volume scan that produced this stock on the list.

The relative volume this week and consequential accumulation triggered

the breakout with those volume spikes

Fundamentally, EYPT had a catalyst as it completed one phase of its

FDA clinical trials for a treatment for macular degeneration, a

debilitating eye disease of the elderly. The potential market

is several multiples of the stock's current market cap.

This company is a takeover candidate as it is young without

a big pipeline but with upside potential.

The relative volume of 4X to 8X is a sure sign that buying

pressure will move the price. Price has crossed the SMA50 just as it

did last winter. The price is up 40% or more this week. Could this be

a pump and dump? Maybe. For sure it is a speculation play just like many

NASDAQ penny biotech stocks For mem the price action of last winter

with a 120% gain in one month is reassurance for this time around

with some hopeium thrown into the mix with the technical analysis.

I will buy a call option under the current price with the 4/21

expiration and leverage the speculation a bit. In the past day,

this option rose 67% based on the price surge of the underlying stock.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.